ELDN SCHEDULE 13G/A: SEC filing

Biotechnology Value Fund and affiliated entities

Filed with the SEC on · accession 0000921895-26-003175

ELDN filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Biotechnology Value Fund and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 9.99% of Eledon Pharmaceuticals' common stock as of September 30, 2026, held through common shares, convertible preferred stock, pre-funded warrants, and Tranche A… The stock moved -6.9% by the first close after the filing.

Summary of the filing

Biotechnology Value Fund and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 9.99% of Eledon Pharmaceuticals' common stock as of September 30, 2026, held through common shares, convertible preferred stock, pre-funded warrants, and Tranche A warrants, subject to 9.99% blocker provisions.

Key details

Aggregate shares beneficially owned by BVF Partners L.P. and BVF Inc.$8.7M
Shares of common stock beneficially owned by Biotechnology Value Fund L.P.$6.1M
Shares of common stock beneficially owned by Biotechnology Value Fund II LP$2.2M
Shares of common stock beneficially owned by Biotechnology Value Trading Fund OS LP$377K
Subject companyEledon Pharmaceuticals, Inc.
Reporting person / beneficial ownerBiotechnology Value Fund, L.P.
Reporting person / beneficial ownerBVF Partners L.P.
Reporting person / beneficial ownerBVF Inc.
Reporting person / control person of bvf inc.Mark N. Lampert

How ELDN stock reacted

Close before

$2.12

Nov 13, 2026

First close after

-6.86%

$1.97

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ELDN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ELDN?

Click here

Frequently asked questions

What did ELDN file with the SEC on Nov 16, 2026?

ELDN filed a SCHEDULE 13G/A (SEC filing). Biotechnology Value Fund and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 9.99% of Eledon Pharmaceuticals' common stock as of September 30, 2026, held through common shares, convertible preferred stock, pre-funded warrants, and Tranche A warrants, subject to 9.99% blocker provisions.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did ELDN stock react to this filing?

ELDN closed at $2.12 before the filing and $1.97 on Nov 16, 2026 (-6.86%).

Other ELDN SEC filings

Get alerts when ELDN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days